Header Logo

Connection

Mark Schmidt to Antiviral Agents

This is a "connection" page, showing publications Mark Schmidt has written about Antiviral Agents.
Connection Strength

1.598
  1. Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure. Hepatol Commun. 2021 03; 5(3):400-411.
    View in: PubMed
    Score: 0.176
  2. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019 10; 26(10):1210-1217.
    View in: PubMed
    Score: 0.160
  3. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int. 2019 06; 39(6):1027-1032.
    View in: PubMed
    Score: 0.155
  4. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019 03; 49(5):599-608.
    View in: PubMed
    Score: 0.155
  5. Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States. Gastroenterology. 2018 02; 154(3):754-758.
    View in: PubMed
    Score: 0.144
  6. Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study. Dig Dis Sci. 2016 12; 61(12):3469-3477.
    View in: PubMed
    Score: 0.131
  7. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. J Viral Hepat. 2016 09; 23(9):718-29.
    View in: PubMed
    Score: 0.127
  8. Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection. Clin Gastroenterol Hepatol. 2016 07; 14(7):1044-1055.e3.
    View in: PubMed
    Score: 0.126
  9. Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identification. Dig Dis Sci. 2014 Dec; 59(12):3053-61.
    View in: PubMed
    Score: 0.113
  10. Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis?C and Cirrhosis. Adv Ther. 2024 Feb; 41(2):744-758.
    View in: PubMed
    Score: 0.055
  11. Persistent pruritus associated with worse quality of life in patients with chronic hepatitis. Liver Int. 2024 Feb; 44(2):577-588.
    View in: PubMed
    Score: 0.054
  12. Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat. 2023 09; 30(9):746-755.
    View in: PubMed
    Score: 0.053
  13. Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017. J Clin Gastroenterol. 2021 01; 55(1):77-83.
    View in: PubMed
    Score: 0.044
  14. Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. Infect Dis Clin North Am. 2018 06; 32(2):253-268.
    View in: PubMed
    Score: 0.037
  15. Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017 Jun; 32(6):1250-1257.
    View in: PubMed
    Score: 0.035
  16. Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings. Clin Infect Dis. 2016 11 01; 63(9):1205-1208.
    View in: PubMed
    Score: 0.033

© 2024 Kaiser Permanente